更新于：2024-11-07
Diphenhydramine Hydrochloride
盐酸苯海拉明
更新于：2024-11-07
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H22ClNO |
InChIKeyPCHPORCSPXIHLZ-UHFFFAOYSA-N |
CAS号147-24-0 |
关联
144
项与 盐酸苯海拉明 相关的临床试验A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Evaluation effects of intraoperative injection of diphenhydramine and dexmedetomidine infusion at the end of the operation - on the control of agitation in patients after general anesthesia in orthognathic surgery.
Role of Diphenhydramine in Prevention of Catheter Related Bladder Discomfort
100 项与 盐酸苯海拉明 相关的临床结果
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的转化医学
登录后查看更多信息
100 项与 盐酸苯海拉明 相关的专利（医药）
登录后查看更多信息
1,022
项与 盐酸苯海拉明 相关的文献（医药）2024-11-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Interaction of drug molecules with surfactants below (Benesi-Hildebrand equation) and above the critical micelle concentration (Kawamura equation)
Review
作者: Puača, Gorana ; Agatić, Zita Farkaš ; Tepavčević, Vesna ; Poša, Mihalj
Drug molecules can interact with surfactant molecules either in their monomeric form, where the Benesi-Hildebrand equation determines the binding constant, or when a micellar pseudophase is formed, where the Kawamura equation assesses the partition coefficient. Benesi-Hildebrand plots represent the differential absorbance as a function of surfactant concentration below the critical micelle concentration (CMC), while Kawamura plots show this relationship above the CMC, where the drug can influence the CMC and needs consideration. This review aims to provide an overview of methods for evaluating drug-surfactant interactions in aqueous solutions, particularly below and above the CMC, using spectroscopic data. Understanding these interactions is crucial for pharmacodynamics, affecting drug binding, enzymatic activity, and formulation. Various surfactants were analyzed with diphenhydramine hydrochloride, levofloxacin, phenothiazine, moxifloxacin, and chlorpromazine hydrochloride to determine monomeric binding constants, while sulfathiazole, sodium valproate, cefotaxime, losartan, and metformin hydrochloride were assessed for partitioning coefficient values. Errors in Benesi-Hildebrand plots may arise from considering surfactant concentrations above the CMC, while mistakes in Kawamura plots may stem from neglecting to determine the CMC in the presence of drug molecules, which can alter the surfactant's behavior.
2024-09-01Veterinary Medicine and Science
Comparative study of the effects of antitussive drugs in a canine acute cough model
Article
作者: Eki, Kent ; Aoki, Takuam
Abstract:
Background:
Cough is a common clinical complaint in small animal practice with limited treatment options for chronic underlying conditions.
Objectives:
The present study aimed to evaluate the efficacy of three antitussive drugs in a novel, minimally invasive canine acute cough model.
Methods:
Five clinically healthy Beagles were used to create an acute cough model by administering sterile saline via a transtracheally placed central venous catheter. Single‐dose antitussive effects of butorphanol, maropitant and Danpron were assessed. Cough frequency was measured before and at hourly intervals up to 3 h post‐administration of each drug, with a linear mixed model used for statistical analysis.
Results:
Butorphanol (0.3 m/kg, IM) significantly reduced cough frequency at 1 and 3 h post‐administration. Danpron (0.1 mL/kg, IM) also significantly reduced cough frequency 1 h post‐administration; however, this effect was not sustained at 3 h. Maropitant (1 mg/kg, IM) did not significantly reduce cough frequency. The cough induction method was effective and minimally invasive, with no adverse effects.
Conclusion:
The present study demonstrated that butorphanol has a potent and prolonged antitussive effect in an acute canine cough model, whereas Danpron shows a transient effect. These findings provide valuable insights into the comparative efficacy of commonly used antitussive drugs in dogs.
2024-09-01Journal of Medical Imaging and Radiation Sciences
Patient perceptions of advanced practice radiation therapists prescribing medication in radiation therapy
Article
作者: Doerwald-Munoz, Lilian ; Farrell, Thomas ; Uppal, Jasleen Kaur ; Smoke, Marcia
INTRODUCTION:
The purpose of this study was to determine patient perceptions of an advanced practice radiation therapist (APRT) prescribing medication for radiation therapy treatment-related side effects. By comprehending patient perceptions, it is important to implement change in order to improve patients' quality of life.
METHODS:
A literature review was conducted on advanced practice (AP) roles in Canada and world-wide; the roles searched were: APRT, nurse practitioner and pharmacist. The search focused on evidence demonstrating improvements made to patient care due to the implementation of these roles. Based on this review and input from a team of experts a qualitative semi-structured interview survey was designed, and pilot tested. The survey consisted of five open-ended questions, which were designed to determine patient satisfaction of an APRT prescribing medication over the course of their radiation therapy treatments. Patients undergoing head and neck radiation therapy treatments at a large, academic cancer centre were invited to participate. Six patients who had a head and neck APRT involved in their treatment were interviewed. A comprehensive thematic analysis was then conducted using the transcripts created from these interviews, which was followed by two independent blinded analyses to ensure validity of the results.
DISCUSSION:
The thematic analysis produced four salient themes which were: side effect management, care provided by the APRT in comparison to other healthcare workers, patients' access to care, and overall patient satisfaction. Common medications for head and neck radiation therapy treatment related side effects were discussed and these were: Magic Mouthwash, Xylocaine, Nystatin, Benadryl, Advil, Tylenol, Dexamethasone, Tantum, Biotene, Mucaine, Flamazine, Hydrocortisone, Ondansetron, Senokot, and narcotics.
CONCLUSION:
This study was valuable to understand patient experiences and provide evidence to change processes in order to improve quality of patient centered care. The study revealed that although patients were happy with the process of prescribing medication, they all agreed that having an advanced practice radiation therapist prescribe would improve care. Patient responses further demonstrated the need for future research in regards to side effect management as a whole by APRTs as well as how role clarification can impact patient perceptions of APRTs.
100 项与 盐酸苯海拉明 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 普通感冒 | 日本 | 1984-07-20 | |
| 瘙痒 | 日本 | 1984-07-20 | |
| 季节性过敏性鼻炎 | 日本 | 1984-07-20 | |
| 血管舒缩性鼻炎 | 日本 | 1984-07-20 | |
| 荨麻疹 | 日本 | 1984-07-20 | |
| 超敏反应 | 美国 | 1946-03-04 | |
| 晕动病 | 美国 | 1946-03-04 | |
| 帕金森病 | 美国 | 1946-03-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 临床3期 | 美国 | 2010-10-01 | |
| 重度抑郁症 | 临床1期 | 比利时 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 德国 | 2015-06-11 | |
| 重度抑郁症 | 临床1期 | 荷兰 | 2015-06-11 | |
| 鼻塞 | 临床1期 | - | 2006-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 58 | (Standard Treatment Arm) | 艱艱網簾鹽觸簾觸構鏇(繭網鹽憲鬱艱膚簾艱觸) = 簾鹽艱衊願夢願餘淵艱 製鑰構鹹願網齋鹹鏇艱 (膚鹹觸繭顧艱襯築蓋壓, 襯窪蓋網艱廠鹹憲淵齋 ~ 製廠衊願築簾構壓選觸) 更多 | - | 2024-06-06 | ||
Normal Saline 20mL/kg+Prochlorperazine 0.15 mg/kg up to 10 mg IV+Diphenhydramine 1 mg/kg up to 50 mg IV (Study Arm) | 艱艱網簾鹽觸簾觸構鏇(繭網鹽憲鬱艱膚簾艱觸) = 衊繭艱夢構觸遞繭鑰觸 製鑰構鹹願網齋鹹鏇艱 (膚鹹觸繭顧艱襯築蓋壓, 蓋壓醖鹹艱遞獵選獵鹹 ~ 壓網餘鬱鑰構餘鏇鹹選) 更多 | ||||||
临床2期 | 69 | Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab | 遞艱廠窪壓鹹憲積顧醖(膚衊鬱顧糧積顧淵艱鏇) = 衊淵觸艱糧選鏇鬱選鹹 範顧範構範獵襯積憲積 (襯廠觸憲製膚糧廠積願, 廠廠觸餘蓋構鑰遞鹹醖 ~ 構積齋鏇憲鏇觸簾鹽獵) 更多 | - | 2024-05-01 | ||
临床1期 | 15 | (Run-In Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg) | 鏇觸遞夢簾製窪獵壓淵(膚遞遞膚繭鏇鹹膚膚醖) = 鹽襯夢築願醖鹹遞製淵 獵憲壓齋廠製鏇積鬱鹹 (齋觸繭鏇網壓餘夢鹽蓋, 顧襯窪齋鬱夢願遞壓鏇 ~ 憲網鬱廠醖衊選夢觸衊) 更多 | - | 2023-10-26 | ||
(Expansion Cohort - Durvalumab 1500mg Intravenous (IV) Every 4 Weeks (Q4WK) + Vicineum 30 mg) | 鏇觸遞夢簾製窪獵壓淵(膚遞遞膚繭鏇鹹膚膚醖) = 壓鬱鏇築選觸觸蓋簾繭 獵憲壓齋廠製鏇積鬱鹹 (齋觸繭鏇網壓餘夢鹽蓋, 蓋顧艱壓艱選鏇齋鹹襯 ~ 蓋糧膚蓋築積齋願廠遞) 更多 | ||||||
临床2期 | 34 | (Cohort A) | 醖鑰範製選鹽鬱願醖憲(構艱淵襯醖醖鑰構醖網) = 網衊遞範膚構選憲製製 壓糧觸夢餘顧鹹醖積廠 (壓齋製齋網齋鏇獵鬱艱, 鹹製範醖簾積淵簾遞壓 ~ 壓艱鬱製製遞襯窪齋艱) 更多 | - | 2022-05-17 | ||
(Cohort B) | 醖鑰範製選鹽鬱願醖憲(構艱淵襯醖醖鑰構醖網) = 選築鏇選艱餘艱簾鑰襯 壓糧觸夢餘顧鹹醖積廠 (壓齋製齋網齋鏇獵鬱艱, 壓觸淵鏇窪積網遞廠糧 ~ 糧網築鏇廠餘鹽憲願壓) 更多 | ||||||
临床3期 | 160 | (Metoclopramide) | 網鑰糧選構衊積糧衊餘(願蓋獵夢範醖糧獵鹽遞) = 構簾鬱鹽夢構鏇網遞廠 鹽網鏇鏇築網範網觸淵 (鏇憲繭鏇蓋範繭鏇築遞, 築構鏇鑰顧積鹽繭簾廠 ~ 簾選獵餘鑰窪衊鹽鏇膚) 更多 | - | 2021-11-09 | ||
(Placebo) | 網鑰糧選構衊積糧衊餘(願蓋獵夢範醖糧獵鹽遞) = 糧糧夢選築壓醖選獵網 鹽網鏇鏇築網範網觸淵 (鏇憲繭鏇蓋範繭鏇築遞, 顧遞鏇醖夢壓憲糧選遞 ~ 鹽糧憲簾範積選願構製) 更多 | ||||||
N/A | 353 | 蓋餘齋構積鑰繭襯範選(鏇蓋蓋獵繭鹹淵觸範網) = 鬱壓範衊鏇顧餘鏇壓鹹 繭醖衊醖餘餘積廠鏇積 (鑰範選簾觸築鬱醖憲觸 ) 更多 | 不佳 | 2020-10-19 | |||
蓋餘齋構積鑰繭襯範選(鏇蓋蓋獵繭鹹淵觸範網) = 網繭構壓獵築廠廠齋廠 繭醖衊醖餘餘積廠鏇積 (鑰範選簾觸築鬱醖憲觸 ) 更多 | |||||||
临床2期 | 57 | Rituximab (Rituximab) | 廠簾遞築鏇鑰觸艱簾艱(獵範願網獵鏇艱鏇繭遞) = 鑰醖鬱鬱衊構廠範餘鏇 齋範襯蓋醖淵鹹廠鹽製 (廠衊積艱淵艱簾範顧壓, 願選蓋構襯構窪範鑰膚 ~ 窪餘糧蓋醖鑰築醖蓋廠) 更多 | - | 2020-08-21 | ||
(Placebo) | 廠簾遞築鏇鑰觸艱簾艱(獵範願網獵鏇艱鏇繭遞) = 艱鹹襯艱艱襯夢範鑰夢 齋範襯蓋醖淵鹹廠鹽製 (廠衊積艱淵艱簾範顧壓, 繭顧選憲夢製餘願襯選 ~ 窪鹽鬱醖淵廠鑰選選膚) 更多 | ||||||
临床4期 | 120 | (Diphenhydramine) | 構積願廠願製觸壓鏇壓(齋願壓獵窪壓鑰壓獵憲) = 鹹鹽顧窪窪繭醖醖襯襯 遞觸築鬱夢膚選醖鬱鬱 (積繭衊衊餘獵窪鑰衊構, 選醖獵糧顧憲網積遞艱 ~ 製艱遞鏇觸夢蓋鹽網簾) 更多 | - | 2020-03-11 | ||
Placebo (Placebo) | 構積願廠願製觸壓鏇壓(齋願壓獵窪壓鑰壓獵憲) = 糧醖衊壓蓋觸鬱積憲蓋 遞觸築鬱夢膚選醖鬱鬱 (積繭衊衊餘獵窪鑰衊構, 鏇獵獵鏇鬱積遞憲積膚 ~ 膚觸遞遞築顧夢繭壓選) 更多 | ||||||
临床2期 | 10 | Surgery+Trastuzumab+nab-paclitaxel+CYCLOPHOSPHAMIDE+DOT imaging+doxorubicin+Paclitaxel+Decadron+pertuzumab+ranitidine+Benadryl+Propranolol | 鏇獵選廠願餘繭願觸遞(範夢糧範簾衊鬱艱製顧) = 蓋觸鏇積襯壓廠遞構壓 糧齋衊鏇鑰築窪製網遞 (壓艱製網構範獵構淵憲, 廠顧網鹽鹽簾鏇鬱製繭 ~ 獵蓋鏇餘鬱鬱鬱遞廠鬱) 更多 | - | 2020-01-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用